GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » EPS without NRI

Verici Dx (LSE:VRCI) EPS without NRI : £-0.05 (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx EPS without NRI?

Verici Dx's earnings per share without non-recurring items for the six months ended in Jun. 2023 was £-0.03. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Verici Dx's EPS without NRI or its related term are showing as below:

LSE:VRCI's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -0.5
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Verici Dx's EPS (Diluted) for the six months ended in Jun. 2023 was £-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.05.

Verici Dx's EPS (Basic) for the six months ended in Jun. 2023 was £-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.05.


Verici Dx EPS without NRI Historical Data

The historical data trend for Verici Dx's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx EPS without NRI Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
EPS without NRI
- -0.04 -0.06

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
EPS without NRI -0.01 -0.03 -0.03 -0.03 -0.03

Competitive Comparison of Verici Dx's EPS without NRI

For the Diagnostics & Research subindustry, Verici Dx's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Verici Dx's PE Ratio without NRI falls into.



Verici Dx EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx  (LSE:VRCI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Verici Dx EPS without NRI Related Terms

Thank you for viewing the detailed overview of Verici Dx's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (LSE:VRCI) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (LSE:VRCI) Headlines

No Headlines